TickerFacts.

Emmaus Life Sciences, Inc. (EMMA): Long-Term Debt

Annual figures by period end, from SEC filings.

$27.13M
As of 2025-12-31
$24.99M
As of 2026-06-30
-3.7%
3-year compound annual growth
+12.1%
5-year compound annual growth
$30.56M2020-12-31: $15.29M2021-12-31: $22.34M2022-12-31: $30.42M2023-12-31: $30.56M2024-12-31: $28.96M2025-12-31: $27.13M$27.13M
2020-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$27.13M-6.3%2026-03-31, Balance as of period end
2024-12-31$28.96M-5.2%2025-04-14, Balance as of period end
2023-12-31$30.56M+0.5%2024-07-03, Balance as of period end
2022-12-31$30.42M+36.2%2023-03-31, Balance as of period end
2021-12-31$22.34M+46.1%2022-03-31, Balance as of period end
2020-12-31$15.29Mn/a2021-08-10, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$27.13M-6.3%
Tonix Pharmaceuticals Holding Corp. (TNXP)2024-12-31$8.65M-21.4%
CV Sciences, Inc. (CVSI)2025-12-31$1.65Mn/a
Arbutus Biopharma Corp (ABUS)2025-12-31$0n/a
Precigen, Inc. (PGEN)2025-12-31$93.17Mn/a
uniQure N.V. (QURE)2025-12-31$71.92M+8.9%
BioAge Labs, Inc. (BIOA)2024-12-31$8.50Mn/a
Verastem, Inc. (VSTM)2024-12-31$40.72M+1.6%
Verrica Pharmaceuticals Inc. (VRCA)2025-12-31$0-100.0%

Compare EMMA, TNXP, CVSI, ABUS side by side · Screen every company in Pharmaceutical Preparations ↗